Ask A Doctor Appointment
Sankara Nethralaya
Sankara Nethralaya
Back to Research
Department of Nanobiotechnology
Therapeutic and Toxicological Evaluation of Anti-Lipogenic Agents in Cancer Cells Compared with Non-Neoplastic Cells.Deepa PR, Vandhana S, Jayanthi U, Krishnakumar S.Basic Clin Pharmacol Toxicol. 2011 Dec 12.
Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mitra M, Misra R, Harilal A, Sahoo SK, Krishnakumar S.Mol Vis. 2011;17:2724-37.
Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Mitra M, Kandalam M, Sundaram CS, Verma RS, Maheswari UK, Swaminathan S, Krishnakumar S.Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5441-8.
Comparative proteomic analysis of differentially expressed proteins in primary retinoblastoma tumors. Mallikarjuna K, Sundaram CS, Sharma Y, Deepa PR, Khetan V, Gopal L, Biswas J, Sharma T, Krishnakumar S.Proteomics Clin Appl. 2010 Apr;4(4):449-63.
Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. Mitra M, Kandalam M, Verma RS, UmaMaheswari K, Krishnakumar S. Mol Vis. 2010 May 11;16:828-42.
Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Parveen S, Mitra M, Krishnakumar S, Sahoo SK. Acta Biomater. 2010 Aug;6(8):3120-31. Epub 2010 Feb 10.
Expression of high mobility group A2 protein in retinoblastoma and its association with clinicopathologic features. Venkatesan N, Kandalam M, Pasricha G, Sumantran V, Manfioletti G, Ono SJ, Reddy MA, Krishnakumar S. J Pediatr Hematol Oncol. 2009 Mar;31(3):209-14.
Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008 Feb; 13(3-4):144-51. Review.
Adithi M, Nalini V, Kandalam M, Krishnakumar S. Expression of p63 and p73 in retinoblastoma: A clinicopathological correlation study. Exp Eye Res. 2008 Jun 21.
Coral K, Narayanasamy A, Madhavan J, Bharathselvi M, Ramakrishnan S, Nandi K, Rishi P, Kasinathan N, Krishnakumar S. Lysyl oxidase (LOX) activity in the ocular tissues and the role of LOX in proliferative diabetic retinopathy and rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci. 2008 Jun 19.
NarayananJanakiraman, Abhilash Mohan, AshwinKannan and PennathurGautamResonance Energy Transfer between protein and rhamnolipid capped ZnS quantum dots: Application in in-gel staining of proteins. SpectrochimicaActa Part A: Molecular and Biomolecular Spectroscopy (2012) Volume 95, September 2012, Pages 478–482
Narayanan J, Ramji R, Sahu H, Gautam P. Synthesis, stabilisation and characterisation of rhamnolipid-capped ZnS nanoparticles in aqueous medium. IET Nanobiotechnol. 2010 Jun;4(2):29-34
NarayananJanakiraman, IndumathyKumaravel, VijinaMuruganAbhilash Mohan, BalasubramanianNatesan, GautamPennathur “Application of Phosphorylated Rhamnolipid as an Antibacterial and Heavy Metal Complexing Agent “ (Under Review)
Process for preparing rhamnolipid capped metal nanoparticles. PennathurGautam, NarayananJanakiraman. Centre for Biotechnology, Anna University, Chennai – 600025, Tamil NaduPatent Application No.2143/CHE/2008. Date of publication: 21/11/2008. The Patent office Journal
Shachaf CM, Elchuri SV, Koh AL, Zhu J, Nguyen LN, Mitchell DJ, Zhang J, SwartzKB, Sun L, Chan S, Sinclair R, Nolan GP. A novel method for detection ofphosphorylation in single cells by surface enhanced Raman scattering (SERS) usingcomposite organic- inorganic nanoparticles (COINs). PLoS One. 2009;4(4):e5206.Epub 2009 Apr 15.
Koh AL, Shachaf CM, Elchuri S, Nolan GP, Sinclair R. Electron microscopy localization and characterization of functionalized composite organic-inorganicSERS nanoparticles on leukemia cells. Ultramicroscopy. 2008 Dec;109(1):111-21.
Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW. Genomic and proteomic analysis reveals a threshold level of MYC required for tumormaintenance. Cancer Res. 2008 Jul 1;68(13):5132-42.
Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE,Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 2007 Oct 1;110(7):2674-84. Epub 2007 Jul 10
Elchuri S, Naeemuddin M, Sharpe O, Robinson WH, Huang TT. Identification of biomarkers associated with the development of hepatocellular carcinoma in CuZnsuperoxide dismutase deficient mice. Proteomics. 2007 Jun;7(12):2121-9.